Fate Therapeutics (FATE) Debt to Equity (2016 - 2019)
Fate Therapeutics (FATE) has disclosed Debt to Equity for 8 consecutive years, with $0.05 as the latest value for Q3 2019.
- For the quarter ending Q3 2019, Debt to Equity fell 39.18% year-over-year to $0.05, compared with a TTM value of $0.05 through Sep 2019, down 39.18%, and an annual FY2018 reading of $0.09, down 51.65% over the prior year.
- Debt to Equity was $0.05 for Q3 2019 at Fate Therapeutics, down from $0.12 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.93 in Q1 2015 and bottomed at $0.05 in Q3 2019.
- Average Debt to Equity over 5 years is $0.3, with a median of $0.23 recorded in 2018.
- The sharpest move saw Debt to Equity surged 3272.26% in 2015, then crashed 80.9% in 2017.
- Year by year, Debt to Equity stood at $0.48 in 2015, then crashed by 69.76% to $0.15 in 2016, then skyrocketed by 31.31% to $0.19 in 2017, then tumbled by 51.65% to $0.09 in 2018, then crashed by 43.96% to $0.05 in 2019.
- Business Quant data shows Debt to Equity for FATE at $0.05 in Q3 2019, $0.12 in Q2 2019, and $0.1 in Q1 2019.